In an interview to India Today, the President of Quality Operation at Bharat Biotech has said that India’s 1st indigenous vaccine could achieve more than 60% efficacy. The WHO, United States Food and Drug Administration, and India's Central Drugs Standard Control Organisation have set the minimum required efficacy for approval at 50%. The trial results so far suggest that the chances of Covaxin’s efficacy being lesser than 50% are remote, Sai D Prasad said. The top official also said that post approvals, they are aiming to begin the rolling-out process in the 2nd quarter of 2021. Covaxin is currently going through Phase-3 trials, in partnership with ICMR, involving 26,000 volunteers across the country.